Uveal melanoma: From diagnosis to treatment and the science in between
C Chattopadhyay, DW Kim, DS Gombos, J Oba, Y Qin… - Cancer, 2016 - Wiley Online Library
Melanomas of the choroid, ciliary body, and iris of the eye are collectively known as uveal
melanomas. These cancers represent 5% of all melanoma diagnoses in the United States …
melanomas. These cancers represent 5% of all melanoma diagnoses in the United States …
Metastatic tumors of the orbit and ocular adnexa
SM Ahmad, B Esmaeli - Current opinion in ophthalmology, 2007 - journals.lww.com
Breast carcinoma continues to account for the majority of metastatic lesions of the orbit and
ocular adnexa. Although the overall prognosis for patients with such lesions remains poor …
ocular adnexa. Although the overall prognosis for patients with such lesions remains poor …
Sebaceous carcinoma: evidence-based clinical practice guidelines
Sebaceous carcinoma usually occurs in adults older than 60 years, on the eyelid, head and
neck, and trunk. In this Review, we present clinical care recommendations for sebaceous …
neck, and trunk. In this Review, we present clinical care recommendations for sebaceous …
Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel
NK Ibrahim, N Desai, S Legha, P Soon-Shiong… - Clinical cancer …, 2002 - AACR
Purpose: ABI-007 is a novel Cremophor-free, protein-stabilized, nanoparticle formulation of
paclitaxel. The absence of Cremophor EL may permit ABI-007 to be administered without …
paclitaxel. The absence of Cremophor EL may permit ABI-007 to be administered without …
[PDF][PDF] Integrative analysis identifies four molecular and clinical subsets in uveal melanoma
AG Robertson, J Shih, C Yau, EA Gibb, J Oba… - Cancer cell, 2017 - cell.com
Comprehensive multiplatform analysis of 80 uveal melanomas (UM) identifies four
molecularly distinct, clinically relevant subtypes: two associated with poor-prognosis …
molecularly distinct, clinically relevant subtypes: two associated with poor-prognosis …
Phase II study of weekly docetaxel and trastuzumab for patients with HER-2–overexpressing metastatic breast cancer
PURPOSE: To evaluate the safety and efficacy of weekly docetaxel plus trastuzumab in
women with HER-2–overexpressing metastatic breast cancer. Efficacy was correlated with …
women with HER-2–overexpressing metastatic breast cancer. Efficacy was correlated with …
Visual outcome and ocular survival after penetrating trauma: a clinicopathologic study
B Esmaeli, SG Elner, MA Schork, VM Elner - Ophthalmology, 1995 - Elsevier
Purpose: Ocular trauma is a leading cause of blindness in the United States. This study was
undertaken to identify clinical and histopathologic factors that predict ocular survival and …
undertaken to identify clinical and histopathologic factors that predict ocular survival and …
Successful treatment of Erdheim-Chester disease, a non–Langerhans-cell histiocytosis, with interferon-α
F Braiteh, C Boxrud, B Esmaeli, R Kurzrock - Blood, 2005 - ashpublications.org
Erdheim-Chester disease is a rare non-Langerhans histiocytosis with multisystem
involvement. To date, there is no standard treatment for this disorder, and more than half of …
involvement. To date, there is no standard treatment for this disorder, and more than half of …
Combination Small Molecule MEK and PI3K Inhibition Enhances Uveal Melanoma Cell Death in a Mutant GNAQ- and GNA11-Dependent Manner
JS Khalili, X Yu, J Wang, BC Hayes, MA Davies… - Clinical Cancer …, 2012 - AACR
Abstract Purpose: Activating Q209L/P mutations in GNAQ or GNA11 (GNAQ/11) are present
in approximately 80% of uveal melanomas. Mutant GNAQ/11 are not currently …
in approximately 80% of uveal melanomas. Mutant GNAQ/11 are not currently …
Canalicular stenosis secondary to docetaxel (taxotere): a newly recognized side effect
B Esmaeli, V Valero, MA Ahmadi, D Booser - Ophthalmology, 2001 - Elsevier
OBJECTIVE: To report a newly recognized side effect of a commonly used antineoplastic
agent, docetaxel, in three patients with metastatic breast cancer. DESIGN: Observational …
agent, docetaxel, in three patients with metastatic breast cancer. DESIGN: Observational …